Giraldo, P. Et Al. 2023. ELIKIDS: baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3. SSIEM Annual Symposium 2023 , (Jerusalem, Israel), 307.

Giraldo, P., GÖKÇAY, G. F., Batsu, İ., Kissell, J., Gaemers, S. J., Li, N., ... Perichon, G.(2023). ELIKIDS: baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3 . SSIEM Annual Symposium 2023 (pp.307). Jerusalem, Israel

Giraldo, Pilar Et Al. "ELIKIDS: baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3," SSIEM Annual Symposium 2023, Jerusalem, Israel, 2023

Giraldo, Pilar Et Al. "ELIKIDS: baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3." SSIEM Annual Symposium 2023 , Jerusalem, Israel, pp.307, 2023

Giraldo, P. Et Al. (2023) . "ELIKIDS: baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3." SSIEM Annual Symposium 2023 , Jerusalem, Israel, p.307.

@conferencepaper{conferencepaper, author={Pilar Giraldo Et Al. }, title={ELIKIDS: baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3}, congress name={SSIEM Annual Symposium 2023}, city={Jerusalem}, country={Israel}, year={2023}, pages={307} }